News

ChromaDex will provide Wageningen University with quantities of its proprietary NIAGEN nicotinamide riboside (NR) ingredient for research use. ChromaDex’s NIAGEN is the first and only commercially available form

Under this collaborative initiative, FORMA and Dr Ovaa will advance the research, discovery and clinical application of highly-selective, irreversible therapeutics. This represents a distinct and additional agreement between

This is the Company’s second IND to be allowed in the past 10 months that uses the Orascovery technology platform for oral delivery of anti-cancer drugs. In July

Under the collaboration, new gene therapy vectors and proprietary molecules will be discovered and developed using the Avalanche Ocular BioFactory, an adeno-associated virus (AAV)-based, proprietary, next-generation platform for

Auven intends to conduct a Phase II (proof-of-concept) clinical trial to evaluate KIACTA’s effectiveness and safety to treat certain medical manifestations of sarcoidosis. Kiacta is aimed at addressing

The DSMB did not identify any safety concerns for the patients enrolled in the trial. Based on the DSMB recommendation and while further review of the data is

The company is currently developing a response to address the items outlined in the letter. Acorda president and CEO Dr Ron Cohen noted that there is an urgent

The Phase III trial results demonstrated that patients administered with pasireotide long-acting release (LAR) achieved greater disease control when compared to continued treatment with the standard somatostatin analogue

The Phase Ib/IIa study will evaluate the safety, tolerability and pharmacokinetics of a single ascending dose of COVA322, a bispecific TNF/IL-17A inhibitor. The randomized, double-blind, placebo-controlled will enroll